What Treatment Options Are Available for Diabetes Patients?

Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.

CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.

VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.

A study author explains how pharmacists can help close vaccination gaps in rural communities and what lower ICU admission rates among vaccinated older adults may mean.

From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.

Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.

Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association, discusses pharmacists’ role in diabetes and CKD care at ASN Kidney Week 2026.

Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.